Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) CFO Ilan Hadar sold 9,420 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $3.50, for a total value of $32,970.00. Following the sale, the chief financial officer now directly owns 123,671 shares of the company’s stock, valued at $432,848.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of FOMX stock traded down $0.04 on Wednesday, hitting $3.61. 894,300 shares of the stock were exchanged, compared to its average volume of 460,191. The firm has a market capitalization of $222.65 million, a P/E ratio of -2.11 and a beta of 1.53. Foamix Pharmaceuticals Ltd has a fifty-two week low of $1.97 and a fifty-two week high of $7.60. The business has a 50-day moving average of $2.81 and a 200 day moving average of $3.02.
Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 75.99%. As a group, equities research analysts expect that Foamix Pharmaceuticals Ltd will post -1.64 earnings per share for the current fiscal year.
Several analysts have commented on FOMX shares. Bank of America restated a “buy” rating and set a $11.00 target price on shares of Foamix Pharmaceuticals in a report on Friday, August 9th. Zacks Investment Research cut shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. ValuEngine raised shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright set a $12.00 price objective on shares of Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 28th. Finally, Barclays started coverage on shares of Foamix Pharmaceuticals in a research report on Tuesday, June 11th. They issued an “overweight” rating and a $10.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $13.96.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Recommended Story: What is the accumulation/distribution indicator?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.